Hematology Roundup: FDA Oks New Thrombocytopenia Drug, MM Risk Reduction, and More

The editors of Consultant360 have compiled a highlight reel of top stories and breaking hematology news from the early months of 2018. See what you may have missed.

The US Food and Drug Administration approved a new treatment option for thrombocytopenia.

The drug is indicated for adults with chronic liver disease who are scheduled to undergo a procedure. It is the first thrombopoietin receptor agonist to be approved for this indication. Read More

Screening patients with a high lifetime risk for multiple myeloma (MM) may lower their risk of MM-related death, researchers said.

In particular, this finding affects patients with monoclonal gammopathy of undetermined significance. Read More

The use of non-steroidal anti-inflammatory drugs (NSAIDs) is tied to an 18% higher risk for atrial fibrillation (AF).

AF risk was compared among users of selective NSAIDs, nonselective NSAIDs, combined selective and nonselective NSAIDs, and non-users. Read More

Risk factors identified for splenectomy in immune thrombocytopenia (ITT).

These findings emerged from a study of 37,844 ITT hospitalizations between 2005 and 2014. Read More

Patients with heparin-induced thrombocytopenia often have poor outcomes.

These findings indicate a need for more effective preventive and treatment interventions, the study authors said. Read More